Liminatus Pharma, Inc. (LIMN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 48/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.2% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
- Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
- Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
- Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
- Liminatus Pharma Announces Nasdaq Delisting Notification
- Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
- Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
- Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Liminatus Pharma, Inc..
Full LIMN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.